CAPRIN-1 Antibody–CDK Inhibitor Combination to Address Drug Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using chemotherapeutics and CDK inhibitors face limitations in efficacy, particularly due to drug resistance and lack of synergistic enhancement, necessitating new therapeutic strategies.
Innovation Solution
A combination of an antibody targeting CAPRIN-1 protein and a CDK inhibitor, such as palbociclib or ribociclib, is used to enhance antitumor effects by increasing phagocytic activity of immunocytes against cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapeutics are used for cancer treatment, then cancer cells are killed, but drug resistance develops and therapeutic effects are limited
Solution Approach 1:
The patent combines an anti-CAPRIN-1 antibody with a CDK inhibitor to create a synergistic therapeutic regimen. The antibody targets cancer cells specifically while the CDK inhibitor blocks cell cycle progression, and together they overcome drug resistance mechanisms that limit chemotherapeutic effectiveness alone.
Solution Approach 2:
The therapeutic composition is a composite formulation integrating two distinct mechanisms of action: an immunological component (antibody) and a molecular targeted component (CDK inhibitor). This composite approach addresses both direct cell killing and resistance prevention simultaneously.
2Reliability
If CDK inhibitors are used to control cell cycle, then cancer cell proliferation is suppressed, but drug efficacy is limited due to emergence of drug resistance
Solution Approach 1:
The CDK inhibitor is combined with an anti-CAPRIN-1 antibody that enhances phagocytic activity of immunocytes. This combination addresses drug resistance by adding an immunological dimension to the molecular targeted therapy, creating a more robust and resistant-proof treatment strategy.
3Reliability
If combination of chemotherapeutics is used, then therapeutic effects are enhanced, but few combinations synergistically drastically enhance effects and most only additively enhance
Solution Approach 1:
The patent identifies specific parameter changes in the combination therapy: using an anti-CAPRIN-1 antibody (rather than generic chemotherapeutics) combined with a CDK inhibitor creates a synergistic effect that drastically enhances therapeutic outcomes compared to additive combinations, while maintaining manageable treatment complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of CAPRIN-1 antibody and CDK inhibitor demonstrates a stronger antitumor effect than either alone, significantly enhancing phagocytic activity against cancer cells, offering a potential solution to drug resistance and improving treatment outcomes.
Implementation Method 1
an antibody or a fragment thereof having an immunological reactivity with CAPRIN-1 protein
Implementation Method 2
a CDK (cyclin-dependent kinase) inhibitor... CDK inhibitors that suppress CDK activities and control the cell cycle
Implementation Method 3
the present invention has the effect of increasing the phagocytic activity against cancer cells by immunocytes
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The medicament comprising an antibody or a fragment thereof having an immunological reactivity with CAPRIN-1 protein, and a CDK inhibitor together or separately in combination is useful for treating and/or preventing cancer.